BSE: 531686 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that MPS Pharmaa Ltd is a below average quality company.
The key valuation ratios of MPS Pharmaa Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of MPS Pharmaa Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0.6% | -4.2% | -33.9% | -5.9% | -7.8% | -8.1% | -36.9% | -9.6% | -11.2% | -9.1% | - |
| Value Creation Index ⓘ | -1.0 | -1.3 | -3.4 | -1.4 | -1.6 | -1.6 | -3.6 | -1.7 | -1.8 | -1.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 12.2 | 1.4 | 2.8 | 4.1 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales YoY Gr. | - | -89% | 110.4% | 44% | -79.7% | -100% | NA | NA | -100% | NA | - |
| Adj EPS ⓘ | -0.5 | -0.6 | -3.9 | -0.5 | -0.7 | -0.6 | -2.4 | -0.1 | -0.6 | -0.4 | -0.5 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 10.7 | 9.9 | 6.1 | 5.6 | 5 | 4.4 | 2.1 | 2 | 1.5 | 1 | 0.8 |
| Adj Net Profit ⓘ | -0.7 | -1.2 | -7.4 | -0.9 | -1.3 | -1.2 | -4.5 | -0.1 | -1.1 | -0.8 | -1 |
| Cash Flow from Ops. ⓘ | 2.2 | 1.3 | 0.4 | -0.3 | 0.6 | -0.5 | -0.9 | -4.3 | -0.9 | -0.6 | - |
| Debt/CF from Ops. ⓘ | 3.6 | 5.3 | 17.9 | -19.5 | 10.5 | -12.8 | -6.1 | -1.3 | -7.8 | -11.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | -100% | NA | NA | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | -22.9% | -27.1% | -20.8% | -29.5% | ||||
| Share Price | -6% | 62% | 48.2% | 48% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -3.4 | -6.2 | -48.3 | -7.7 | -12.3 | -13 | -73.7 | -3.6 | -31.8 | -34.9 | -51.4 |
| Op. Profit Mgn % ⓘ | 6.6 | -36.4 | -242 | -12.8 | -86.8 | -15362.1 | 0 | -2079.4 | 0 | 0 | NAN |
| Net Profit Mgn % ⓘ | -5.5 | -87.9 | -259.8 | -21.1 | -150.5 | -26692.7 | 0 | -437.3 | 0 | 0 | -INF |
| Debt to Equity ⓘ | 0.5 | 0.4 | 0.6 | 0.6 | 0.7 | 0.8 | 1.4 | 1.5 | 2.4 | 3.7 | 0 |
| Working Cap Days ⓘ | 532 | 4,113 | 1,300 | 621 | 2,611 | 4,39,267 | 0 | 23,660 | 0 | 0 | 0 |
| Cash Conv. Cycle ⓘ | 336 | 3,209 | 1,017 | 413 | 1,651 | 2,62,890 | 0 | 9,803 | 0 | 0 | 0 |
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years 0.00%
Debt to equity has increased versus last 3 years average to 3.69
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -0.5 | - |
| TTM Sales (₹ Cr.) | 0 | - |
| BVPS (₹.) ⓘ | 0.8 | - |
| Reserves (₹ Cr.) ⓘ | -18 | - |
| P/BV ⓘ | 5.18 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 2.79 / 4.14 |
| All Time Low / High (₹) | 0.32 / 53.25 |
| Market Cap (₹ Cr.) | 7.9 |
| Equity (₹ Cr.) | 19.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 | 16.04 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0 | 0 | 0.03 | 0 | 0 |
| Operating Expenses ⓘ | 11.43 | 1.85 | 9.72 | 4.62 | 1.55 | 0.68 | 4.13 | 0.71 | 0.95 | 0.80 |
| Manufacturing Costs | 0.21 | 0.18 | 0.29 | 0.15 | 0.05 | 0.06 | 0.07 | 0.06 | 0.21 | 0.07 |
| Material Costs | 9.79 | 0.41 | 8.22 | 3.51 | 0.82 | 0 | 0 | 0.05 | 0.04 | 0 |
| Employee Cost | 0.78 | 0.78 | 0.79 | 0.65 | 0.49 | 0.45 | 0.40 | 0.42 | 0.49 | 0.53 |
| Other Costs ⓘ | 0.65 | 0.47 | 0.42 | 0.30 | 0.18 | 0.17 | 3.66 | 0.18 | 0.21 | 0.20 |
| Operating Profit ⓘ | 0.81 | -0.49 | -6.88 | -0.53 | -0.72 | -0.67 | -4.13 | -0.67 | -0.95 | -0.80 |
| Operating Profit Margin (%) | 6.6% | -36.4% | -242.0% | -12.8% | -86.8% | -15,422.5% | - | -2,079.4% | - | - |
| Other Income ⓘ | 0 | 0 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 |
| Interest ⓘ | 1.08 | 0.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -0.91 | -1.20 | -7.44 | -1.06 | -1.29 | -1.24 | -4.49 | -0.93 | -1.07 | -0.85 |
| Tax ⓘ | -0.24 | -0.01 | -0.06 | -0.19 | -0.05 | -0.07 | -0.08 | -0.79 | -0.02 | -0.02 |
| Profit After Tax | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 |
| PAT Margin (%) | -5.5% | -87.8% | -259.0% | -21.1% | -150.0% | -26,735.0% | - | -437.0% | - | - |
| Adjusted EPS (₹) | -0.5 | -0.6 | -3.9 | -0.5 | -0.7 | -0.6 | -2.3 | -0.1 | -0.6 | -0.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 16.09 | 18.98 | 11.61 | 10.76 | 9.53 | 8.36 | 3.95 | 3.83 | 2.79 | 1.97 |
| Share Capital ⓘ | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves ⓘ | 1.06 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 5.95 | 3.87 | 2.90 | 2.90 | 2.51 | 2.54 | 1.93 | 5.81 | 6.76 | 7.27 |
| Long Term Debt | 1.96 | 0.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 3.99 | 2.90 | 2.90 | 2.90 | 2.51 | 2.54 | 1.93 | 5.81 | 6.76 | 7.27 |
| Trade Payables | 3.30 | 0.64 | 0.36 | 0.14 | 0.16 | 0.15 | 0.09 | 0.12 | 0.20 | 0.20 |
| Others Liabilities ⓘ | 7.02 | 5.08 | 6.06 | 5.36 | 5.36 | 5.37 | 5.33 | 0.40 | 0.43 | 0.49 |
| Total Liabilities ⓘ | 32.36 | 28.57 | 20.93 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 |
Fixed Assets | ||||||||||
| Gross Block | 16.09 | 16.15 | 16.16 | 16.16 | 16.16 | 16.05 | 15.71 | 15.72 | 15.84 | 15.86 |
| Accumulated Depreciation | 7.89 | 8.51 | 9.10 | 9.69 | 10.28 | 10.79 | 11.04 | 11.55 | 11.70 | 11.84 |
| Net Fixed Assetsⓘ | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 |
| CWIP ⓘ | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 |
| Investmentsⓘ | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 |
| Inventories | 7.36 | 7.53 | 1.13 | 0.57 | 0.57 | 0.57 | 0.57 | 0.55 | 0.50 | 0.50 |
| Trade Receivables | 7.68 | 4.27 | 4.14 | 3.86 | 2.61 | 2.53 | 0.59 | 0.03 | 0.03 | 0.02 |
| Cash Equivalents | 0.02 | 0.03 | 0.06 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Others Assetsⓘ | 2.01 | 2.03 | 2.11 | 2.11 | 2.12 | 2.09 | 1.02 | 1.43 | 1.57 | 1.60 |
| Total Assets ⓘ | 32.36 | 28.57 | 20.93 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2.16 | 1.25 | 0.37 | -0.34 | 0.60 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 |
| PBT ⓘ | -0.91 | -1.20 | -7.43 | -1.06 | -1.29 | -1.24 | -4.49 | -0.56 | -1.05 | -0.84 |
| Adjustment ⓘ | 1.75 | 0.74 | 0.61 | 0.62 | 0.60 | 0.59 | 0.58 | 0.51 | 0.15 | 0.15 |
| Changes in Working Capital ⓘ | 1.32 | 1.89 | 7.2 | 0.1 | 1.29 | 0.15 | 2.98 | -4.3 | 0.04 | 0.06 |
| Tax Paid ⓘ | 0 | -0.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -0.44 | -0.05 | 0.63 | 0.30 | -0.21 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 |
| Capex | -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.05 | 0.03 | -0.01 | -0.12 | -0.02 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0.39 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0.01 | 0.41 | 1.13 | 0.47 | 0.02 | 0.14 |
| Cash Flow From Financing Activityⓘ | -1.75 | -1.19 | -0.98 | 0 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 |
| Net Proceeds from Shares ⓘ | 0 | 0.97 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -1.04 | -0.98 | -0.98 | 0 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 |
| Interest Paid ⓘ | -1.07 | -0.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0.36 | -1.10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | -0.03 | 0.01 | 0.02 | -0.04 | 0 | 0 | 0 | 0 | -0.01 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -4.03 | -6.79 | -48.3 | -7.74 | -12.28 | -13.04 | -71.73 | -3.64 | -31.75 | -34.92 |
| ROCE (%) | 0.59 | -4.23 | -33.9 | -5.91 | -7.76 | -8.08 | -36.9 | -9.64 | -11.15 | -9.06 |
| Asset Turnover Ratio | 0.36 | 0.04 | 0.12 | 0.2 | 0.05 | 0 | 0 | 0 | 0 | 0 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Working Capital Days |
| Receivable Days | 243 | 1,592 | 515 | 357 | 1,426 | 0 | 0 | 3,546 | 0 | 0 |
| Inventory Days | 211 | 1,982 | 531 | 76 | 252 | 0 | 0 | 6,294 | 0 | 0 |
| Payable Days | 145 | 1,758 | 22 | 26 | 66 | 0 | 0 | 770 | 1,304 | 0 |
Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.
Advik Laboratories was established in the 1994. It is WHO-GMP certified company that has been set up from the ground level with the avowed objective of achieving USFDA standards of quality.
The company has a technical collaboration with PFC Pharma Focus of Switzerland. It enjoys leadership status at various fronts such as high product quality, a growing range of products, state of the art manufacturing process, competitive pricing and customer service. In addition the company exports a wide range of drugs to the Middle East, South America and Africa.
The product range includes ethical, generic drugs and over the counter drugs (OTC) in various formulations.
With over 60,000 square feet of built-up area, ample developed open space around it, a state-of-the-art manufacturing facility, the ground floor has provisions for the production and in-process control section for the manufacturing of steroidal & non-steroidal formulations, change room for gents & ladies and stores for raw & packing materials. The first floor has provision for the production and in-process control section for the manufacturing of ampicillin and non-ampicillin capsules and dry syrup preparations. The second floor has provision for quality control and about 12000 sq ft area is presently being reserved for the manufacture of injectables & ointments in the second phase.
Advik Laboratories provides pharmaceutical formulations that match the international standards of quality. The facility manufactures a wide range of pharmaceuticals formulations in tablets, capsules and dry syrups.
Products - Under Ethical products, the company manufactures Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin and Chewfe-C.
Under generic products, the company manufactures drugs catering segment such as antibacterials, antiallergics, antifungals, analgesic, antipyretic and anti-inflammatory, anti-hypertensives, anthelminthics, anti-malarials, corticosteroids, erectile dysfunction, gastrointestinal agents and sedatives.
Award - Advik Laboratories has received the prestigious Udyog Patra Award from the Government of India in 1999.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
